ACTIVON, INC. – Trademark Portfolio

Entity Type: 03

ACTIVON, INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 11 (Environmental Control) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include ACTIVON, ACTACEPT, EFFERSAN, and EFFERCEPT. The owner is based in BEAVER DAM, WI.

123 Commercial Drive

BEAVER DAM, WI 53916

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

ACTIVON, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

11
Environmental Control (1 filing)

Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying

Frequently Asked Questions

How many trademarks does ACTIVON, INC. have?

ACTIVON, INC. has 10 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 1 abandoned, 4 cancelled.

What trademark classes does ACTIVON, INC. file in?

ACTIVON, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 11 (Environmental Control). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are ACTIVON, INC.'s most well-known trademarks?

ACTIVON, INC.'s registered trademark portfolio includes well-known marks such as ACTIVON, ACTACEPT, EFFERSAN, and EFFERCEPT. These are among 4 currently registered trademarks in the portfolio.

What is ACTIVON, INC.'s trademark registration success rate?

ACTIVON, INC. has a 44% trademark registration rate, with 4 out of 9 resolved applications resulting in successful registration. Currently, 1 application is pending review.